Blue Trust Inc. Trims Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Blue Trust Inc. reduced its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 9.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,733 shares of the medical equipment provider’s stock after selling 408 shares during the period. Blue Trust Inc.’s holdings in Intuitive Surgical were worth $1,834,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in ISRG. Moss Adams Wealth Advisors LLC grew its position in Intuitive Surgical by 20.1% during the 3rd quarter. Moss Adams Wealth Advisors LLC now owns 627 shares of the medical equipment provider’s stock worth $308,000 after purchasing an additional 105 shares during the period. KMG Fiduciary Partners LLC boosted its stake in shares of Intuitive Surgical by 1.0% in the third quarter. KMG Fiduciary Partners LLC now owns 14,228 shares of the medical equipment provider’s stock worth $6,990,000 after buying an additional 140 shares during the last quarter. Net Worth Advisory Group acquired a new stake in Intuitive Surgical during the third quarter worth about $800,000. Stratos Wealth Advisors LLC raised its position in Intuitive Surgical by 2.7% during the third quarter. Stratos Wealth Advisors LLC now owns 6,095 shares of the medical equipment provider’s stock valued at $2,994,000 after acquiring an additional 162 shares in the last quarter. Finally, Stratos Wealth Partners LTD. raised its position in Intuitive Surgical by 5.8% during the third quarter. Stratos Wealth Partners LTD. now owns 17,663 shares of the medical equipment provider’s stock valued at $8,677,000 after acquiring an additional 976 shares in the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on ISRG. Evercore ISI reaffirmed a “cautious” rating on shares of Intuitive Surgical in a research note on Friday. BTIG Research set a $535.00 price target on shares of Intuitive Surgical in a research report on Friday. Redburn Atlantic upgraded shares of Intuitive Surgical from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $380.00 to $510.00 in a research report on Friday, August 2nd. Piper Sandler restated an “overweight” rating and set a $538.00 target price (up from $495.00) on shares of Intuitive Surgical in a research report on Friday. Finally, Robert W. Baird lifted their price target on Intuitive Surgical from $503.00 to $565.00 and gave the company an “outperform” rating in a research note on Thursday. One analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Intuitive Surgical has an average rating of “Moderate Buy” and a consensus price target of $513.74.

Intuitive Surgical Stock Up 10.0 %

Intuitive Surgical stock opened at $521.15 on Friday. The company has a fifty day simple moving average of $483.85 and a 200-day simple moving average of $438.17. The firm has a market capitalization of $184.85 billion, a price-to-earnings ratio of 94.07, a PEG ratio of 5.40 and a beta of 1.39. Intuitive Surgical, Inc. has a 52-week low of $254.85 and a 52-week high of $523.34.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, topping analysts’ consensus estimates of $1.54 by $0.24. The firm had revenue of $2.01 billion for the quarter, compared to analyst estimates of $1.97 billion. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. Intuitive Surgical’s quarterly revenue was up 14.5% on a year-over-year basis. During the same period in the previous year, the business posted $1.18 earnings per share. On average, research analysts anticipate that Intuitive Surgical, Inc. will post 5.22 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Mark Brosius sold 2,115 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $491.91, for a total value of $1,040,389.65. Following the completion of the sale, the insider now directly owns 295 shares in the company, valued at $145,113.45. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, insider Mark Brosius sold 2,115 shares of the business’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $491.91, for a total transaction of $1,040,389.65. Following the transaction, the insider now owns 295 shares of the company’s stock, valued at approximately $145,113.45. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Henry L. Charlton sold 40,243 shares of the company’s stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the completion of the sale, the senior vice president now directly owns 3,001 shares of the company’s stock, valued at $1,461,006.84. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 53,120 shares of company stock valued at $25,528,753 in the last ninety days. 0.90% of the stock is currently owned by corporate insiders.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.